Emerging Markets Earnings Roundup: BMS, Eli Lilly (Part 3)
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly now separates emerging market revenue, cautioning against quarterly volatility, while Bristol-Myers Squibb has little to say about emerging markets during its Q3 earnings call.